ATX-304

ATX-304 is a small-molecule, direct activator of AMP-activated protein kinase (AMPK), the enzyme that acts as the body's central energy sensor and coordinator of metabolism. AMPK is switched on when cellular energy runs low, and it responds by promoting energy-producing pathways such as fatty acid oxidation and glucose uptake while suppressing energy-consuming ones such as lipid and cholesterol synthesis. Because this makes AMPK an attractive target for metabolic disease, drug developers have pursued direct AMPK activators; ATX-304 is a pan-AMPK activator, meaning it activates the full range of AMPK complexes rather than a single isoform ^[1].

ATX-304 is an investigational compound studied in preclinical models rather than an approved drug. In a mouse model of progressive fatty liver disease (metabolic dysfunction-associated steatotic liver disease, or MASLD), ATX-304 reduced body fat mass, lowered blood cholesterol, and mitigated liver steatosis and fibrosis, accompanied by a shift in the liver's metabolic program toward increased fatty acid oxidation and reduced lipid synthesis ^[2]. In a separate line of work, ATX-304 protected mouse kidneys against cisplatin-induced acute kidney injury through AMPK-dependent metabolic reprogramming, an effect lost in AMPK-null cells, confirming that its action runs through AMPK ^[1].

ATX-304 belongs to a broader class of direct AMPK activators that includes compounds such as MK-8722 and SC4, which have demonstrated powerful effects on glucose homeostasis in animals but also revealed class considerations such as cardiac hypertrophy with indiscriminate systemic activation ^[3][4]. As a preclinical agent, ATX-304 has no regulatory approval and no established human safety profile, and it is encountered as a research chemical.

Safety in humans is unknown; ATX-304 has not entered human trials. Preclinical work reported metabolic benefits without obvious toxicity, but AMPK is a master metabolic regulator and off-target or long-term effects in people are uncharacterized. Research-only.

ATX-304, also designated O304, is a direct pan-activator of AMP-activated protein kinase developed out of research at Umea University in Sweden and its associated biotechnology company Betagenon AB. The compound was introduced to the wider scientific community by Steneberg and colleagues in a 2018 JCI Insight report, which showed that O304 increased skeletal-muscle glucose uptake, reduced beta-cell stress and improved microvascular perfusion in diet-induced obese mice, and, notably, lowered fasting glucose and insulin resistance in a proof-of-concept phase IIa trial in type 2 diabetes patients already taking metformin. Subsequent work from the same group, including a 2021 study of pancreatic islet gene expression, further detailed how the compound reprograms metabolism. It continues to be studied as an investigational metabolic activator and has not received regulatory approval.

ATX-304 is discussed as a next-generation metabolic activator, and its central appeal is that it switches on AMPK, the cell's master energy sensor, to mimic several of the downstream effects of exercise from within the cell. The preclinical case is attractive and multifaceted; it reprograms metabolism toward fat oxidation and away from lipid and cholesterol synthesis, reducing body fat, cholesterol and fatty liver in animal models, and it has shown a striking protective effect on the kidney that disappears in AMPK-null cells, confirming the mechanism.

Encouragingly, it has already produced early human signals in a small phase IIa diabetes trial, which is more than many research compounds can claim. Balanced against this, it remains investigational, and its drug class carries a documented caution that unrestrained systemic AMPK activation can enlarge the heart, so its long-term safety profile is still being established.